| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Oncolytic Viruses | Oncology | ||
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Oncolytic Viruses | Oncology | ||
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Oncolytic Viruses | Oncology |
Recent Updates
Recently added Catalysts
CG Oncology, Inc.$75.24
+1.68 (+2.29%)
C 41Pipeline Score Richly Valued Biotech · Clinical
Market Cap
5.67 B
EPS
-2.34
P/E Ratio
-
Value Trade
53.85 M
SEC Financials
Q1 2026Dilution Risk
Revenue
1.08 M
R&D Expenses
43.73 M
Operating CF
-56.94 M
Total Assets
1.14 B
Total Liabilities
43.48 M
Equity
1.09 B
D/E Ratio
12,345
-7.15 %
Week
-11.49 %
1 Month
14.87 %
3 Month
59.59 %
6 Month
121.55 %
5 Year
121.55 %
All Time
Cash Data
Cash Position
1.08 B
Monthly Burn
18.98 M
Runway
54.8 mo
Burn Trend
SEC Filing
May 8, 2026
Overview
Volume
1.04 M
52 Week Range
23.65 - 75.50
% held by Insiders
35.27 %
% held by Institutions
85.07 %
Enterprise Value
4.60 B
Total Shares
80.71 M
Short %
21.7 %
Float Shares
55.61 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for CG Oncology, Inc.
105Total events
2Upcoming
43Tier-1 (high impact)
2023 – 2026Coverage
Upcoming catalysts 2
Event history 103
Jun 9, 2026
◆Oral PresentationPresentation
CG Oncology at Goldman Sachs 47th Annual Global Healthcare Conference
Jun 3, 2026
May 20, 2026
◆Oral PresentationPresentation
RBC Capital Markets Global Healthcare Conference fireside chat
May 19, 2026
●Oral PresentationPresentation
2025 NMIBC Research Fellowship grant recipients presented research at SUO 2026 Annual Meeting at the AUA
Non-Muscle Invasive Bladder Cancersource ↗
May 16, 2026
◆Oral PresentationcretostimogenePresentation
First results from CORE-008 Cohort CX presented at AUA 2026
HR NMIBC BCG-exposed and BCG-unresponsivesource ↗
May 12, 2026
Mar 2, 2026
◆Oral PresentationPresentation
CG Oncology to present at TD Cowen 46th Annual Health Care Conference
Q1 2026
◆Topline Readoutcretostimogene grenadenorepvecClinical Data
Topline data for PIVOT-006 Phase 3 trial of cretostimogene monotherapy in intermediate-risk NMIBC expected in 1H 2026
intermediate-risk non-muscle invasive bladder cancersource ↗
Drug Pipeline Intelligence
C41
Pipeline Score $205M
Pipeline ValueRichly Valued
Valuation Signal2
Drugs Scored0.0x
rNPV / MCap Top 59%
Small Cap (rank 375 of 911)
Percentile RankCG Oncology, Inc. carries a moderate pipeline score (41/100), with $315M risk-adjusted pipeline value, led by Cretostimogene Grenadenorepvec in Non Muscle Invasive Bladder Cancer (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cretostimogene Grenadenorepvec Small molecule | Non Muscle Invasive Bladder Cancer | Phase 3 | NCT06111235 | 42% | $168M | ACTIVE NOT_RECRUITING | 557 | AVERAGE | C (53) | Feb 1, 2029 | MODERATE_RISK | MEDIUM Jul 2, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
cretostimogene | high-risk non-muscle invasive bladder cancer | — | 2025-12-08 | BOND 003 Cohort P: 3 month HG EFS 95.7% (95% CI 83.8 – 98.9), 6 month HG EFS 84.6% (95% CI 68.6 – 92.9), 9 month HG EFS 80.4% (95% CI 62.3-90.4); CORE 008 Cohort A: overall CR rate 83.7% (41/49) (95% CI 70.3-92.7%), original administration CR rate 79.2% (57.8, 92.9), optimized administration CR rate 88.0% (68.8, 97.5) Read More | New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer Read More | |
cretostimogene | high-risk non-muscle invasive bladder cancer | — | 2025-12-08 | BOND 003 Cohort P: 3 month HG EFS 95.7% (95% CI 83.8 – 98.9), 6 month HG EFS 84.6% (95% CI 68.6 – 92.9), 9 month HG EFS 80.4% (95% CI 62.3-90.4); CORE 008 Cohort A: overall CR rate 83.7% (41/49) (95% CI 70.3-92.7%), original administration CR rate 79.2% (57.8, 92.9), optimized administration CR rate 88.0% (68.8, 97.5) Read More | New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer Read More | |
cretostimogene | high-risk non-muscle invasive bladder cancer | — | 2025-12-08 | BOND 003 Cohort P: 3 month HG EFS 95.7% (95% CI 83.8 – 98.9), 6 month HG EFS 84.6% (95% CI 68.6 – 92.9), 9 month HG EFS 80.4% (95% CI 62.3-90.4); CORE 008 Cohort A: overall CR rate 83.7% (41/49) (95% CI 70.3-92.7%), original administration CR rate 79.2% (57.8, 92.9), optimized administration CR rate 88.0% (68.8, 97.5) Read More | New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CGON
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CGON Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CGONCG Oncology to Present at Upcoming Investor Conferences in June 2026
CG Oncology, Inc. announced that its CEO, Arthur Kuan, will present at two major investor conferences in June 2026. The events include the Jefferies Global Healthcare Conference on June 3 and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9. These presentations aim to enhance investor engagement and showcase the company's focus on bladder cancer therapies.
Read more →CGONCG Oncology to Present at Upcoming Investor Conferences in June
CG Oncology, Inc. has announced that its CEO, Arthur Kuan, will present at two significant investor conferences in June 2026. The events include the Jefferies Global Healthcare Conference in New York and the Goldman Sachs 47th Annual Global Healthcare Conference in Miami. These presentations aim to enhance investor engagement and showcase the company's advancements in bladder cancer therapies.
Read more →CGONSUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
CG Oncology and SUO-CTC have announced the recipients of the second annual NMIBC Research Fellowship. Dr. Patrick Hensley and Dr. Daniel Joyce each received grants of up to $50,000 to advance research in non-muscle invasive bladder cancer. Previous awardees presented their findings at the SUO 2026 Annual Meeting, showcasing significant advancements in the field.
Read more →CGONCG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
CG Oncology has reported promising results from its CORE-1008 Cohort CX Phase 2 trial, which evaluates the combination of cretostimogene grenadenorepvec and gemcitabine in patients with high-risk non-muscle invasive bladder cancer. The trial demonstrated high complete response rates and favorable event-free survival rates. The findings suggest that this combination therapy could enhance treatment options for patients who are BCG-exposed or unresponsive.
Read more →CGONCG Oncology’s Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC
CG Oncology will participate in the AUA 2026 Annual Meeting, presenting results from the CORE-008 Cohort CX Phase 2 Trial. This trial evaluates an intravesical combination therapy for patients with high-risk BCG-exposed and BCG-unresponsive non-muscle invasive bladder cancer. The company aims to advance innovative therapies and will exhibit at booth #3051.
Read more →CGONCG Oncology Reports…
CG Oncology reported its financial results for Q1 2026, highlighting a strong cash position of $1.1 billion and progress towards completing its BLA submission for HR BCG-unresponsive NMIBC by Q4 2026. The company anticipates topline data from the Phase 3 PIVOT-006 trial and results from the Phase 2 CORE-008 trial in the near future. Despite these advancements, CG Oncology reported a net loss of $60.2 million, reflecting increased R&D and G&A expenses.
Read more →CGONCG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates
CG Oncology reported its Q1 2026 financial results, highlighting a strong cash position of $1.1 billion. The company is on track to complete its BLA submission for HR BCG-unresponsive NMIBC by Q4 2026. Key upcoming milestones include topline data from the Phase 3 PIVOT-006 trial and results from the Phase 2 CORE-008 trial, both expected in 2026.
Read more →CGONCG Oncology to Present…
CG Oncology, Inc. announced that its CEO Arthur Kuan and COO Ambaw Bellete will participate in fireside chats at two upcoming investor conferences: the Bank of America Health Care Conference on May 12 and the RBC Capital Markets Global Healthcare Conference on May 20. The presentations will be accessible via live audio webcast on the company's website.
Read more →CGONCG Oncology to Present at Upcoming Investor Conferences in May
CG Oncology, Inc. will present at two upcoming investor conferences in May 2026. CEO Arthur Kuan and COO Ambaw Bellete will participate in fireside chats at the Bank of America Health Care Conference on May 12 and the RBC Capital Markets Global Healthcare Conference on May 20. These events aim to enhance investor engagement and showcase the company's developments in bladder cancer therapies.
Read more →CGONCG Oncology Reports 2025 Year End Financial Results and Provides Business Updates
CG Oncology reported its financial results for 2025 and provided updates on its clinical trials. The company anticipates topline data from the PIVOT-006 Phase 3 trial and CORE-008 Phase 2 trial in the first half of 2026. With a strong cash position, CG Oncology aims to establish cretostimogene as a leading therapy for intermediate-risk and high-risk NMIBC patients. However, the company also reported increased losses and rising expenses.
Read more →CGONCG Oncology to Present at the TD Cowen 46th Annual Health Care Conference
CG Oncology, Inc. will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026. CEO Arthur Kuan and COO Ambaw Bellete will lead the presentation, which can be accessed via a live audio webcast. The company aims to develop innovative therapies for bladder cancer patients.
Read more →CGONCG Oncology to Present…
CG Oncology, Inc. announced that its CEO Arthur Kuan and COO Ambaw Bellete will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026. The conference will take place at the Boston Marriott Copley Place. Interested parties can access the live audio webcast from the company's Investor Relations section.
Read more →CGON▲ +29.3%on this news
CG Oncology Provides…
CG Oncology has announced an expedited timeline for the topline data readout of the PIVOT-006 Phase 3 clinical trial, now expected in the first half of 2026. This trial evaluates the efficacy of cretostimogene grenadenorepvec in patients with intermediate-risk non-muscle invasive bladder cancer (IR NMIBC). The trial is notable for being the first randomized registrational study in this patient population, aiming to address a significant unmet medical need.
Read more →CGON▲ +29.3%on this newsshared move
CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC
CG Oncology has announced an expedited timeline for topline data from the PIVOT-006 Phase 3 trial, now expected in the first half of 2026. This trial evaluates cretostimogene for intermediate-risk non-muscle invasive bladder cancer (NMIBC) and is the first randomized study in this patient group. The rapid enrollment across over 90 sites highlights the urgent need for treatment options in this area.
Read more →CGONCG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
CG Oncology, a late-stage clinical biopharmaceutical company, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026. The presentation will be led by CEO Arthur Kuan and COO Ambaw Bellete. Interested parties can access the live audio webcast through the company's website.
Read more →CGONSUO-CTC and CG Oncology…
SUO-CTC and CG Oncology have announced the second annual NMIBC Research Fellowship, aimed at enhancing clinical cancer research for Non-Muscle Invasive Bladder Cancer. Two applicants will receive grants of $50,000 each to support their research. Applications are due by February 27, 2026, and the completed projects will be presented at the AUA annual meeting.
Read more →CGONSUO-CTC and CG Oncology Announce the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
CG Oncology and SUO-CTC have announced the second annual NMIBC Research Fellowship, offering two grants of $50,000 each. This initiative aims to foster clinical cancer research focused on Non-Muscle Invasive Bladder Cancer (NMIBC). Applications are due by February 27, 2026, and selected projects will be presented at the AUA annual meeting.
Read more →CGONNew Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer
CG Oncology announced positive topline data from BOND-003 Cohort P and CORE-008 Cohort A, indicating that cretostimogene may serve as a backbone therapy for high-risk non-muscle invasive bladder cancer (NMIBC). The results show high-grade event-free survival rates and a favorable safety profile, with no serious adverse events reported. These findings will be presented at the Society of Urologic Oncology's annual meeting.
Read more →CGONSUO 2025 – TOPLINE RESULTS FROM BOND-003 COHORT P PODIUM
CG Oncology is set to present topline results from the BOND-003 cohort at the SUO 2025 conference. This follows a series of recent positive developments, including successful trial results and participation in various investor conferences. The company continues to engage with the bladder cancer research community.
Read more →CGONSUO 2025 – FIRST RESULTS CORE-008 COHORT A PODIUM
CG Oncology has announced positive initial results from the CORE-008 Cohort CX Phase 2 trial. This trial evaluates an intravesical combination therapy aimed at high-risk patients who are either BCG-exposed or BCG-unresponsive. The findings suggest potential advancements in treatment options for these patients.
Read more →CGONNew Cretostimogene…
CG Oncology announced promising topline data for cretostimogene from the BOND-003 and CORE-008 trials, indicating its potential as a backbone therapy for high-risk non-muscle invasive bladder cancer (NMIBC). The BOND-003 trial showed high-grade event-free survival rates of 95.7%, 84.6%, and 80.4% at 3, 6, and 9 months, respectively. CORE-008 demonstrated an 88% complete response rate in high-risk BCG-naïve NMIBC patients. The results highlight the drug's efficacy, safety, and tolerability.
Read more →CGONSUO 2025 – CRETO-EAP TIPS EPOSTER
CG Oncology is set to present at the SUO 2025 conference, showcasing their ongoing commitment to advancing research in bladder cancer. The company has recently reported positive results from their CORE-1008 Phase 2 trial, which focuses on a combination therapy for high-risk patients. Additionally, they have announced award recipients for their Non-Muscle Invasive Bladder Cancer Research Fellowship.
Read more →CGONSUO 2025 – CORE-008 COHORT B TIPS EPOSTER
CG Oncology has announced positive initial results from the CORE-008 Cohort CX Phase 2 trial. This trial focuses on an intravesical combination therapy for patients who are high-risk and either BCG-exposed or BCG-unresponsive. The findings are expected to contribute significantly to treatment options for these patients.
Read more →CGONSUO 2025 – FINAL RESULTS BOND-003 COHORT C EPOSTER
CG Oncology has announced its participation in various upcoming conferences, including presentations related to the BOND-003 Cohort C and CORE-1008 trials. The company is also involved in promoting research in non-muscle invasive bladder cancer through fellowship awards. Recent results from their trials have been positive, indicating progress in their treatment approaches.
Read more →CGONCG Oncology Announces New Board Member and Board Transition
CG Oncology has appointed Christina Rossi to its Board of Directors, enhancing its leadership as it prepares for the launch of cretostimogene, an investigational immunotherapy for bladder cancer. The company also announced the resignation of Simone Song from the board. Rossi brings over 25 years of experience in the pharmaceutical industry, having held senior roles at Blueprint Medicines and Sanofi Genzyme.
Read more →CGONCG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual Meeting
CG Oncology will present significant findings on cretostimogene grenadenorepvec at the SUO 26th Annual Meeting. The presentations will cover topline results from the BOND-003 and CORE-008 trials, focusing on high-risk bladder cancer patients. This highlights the drug's potential as a key immunotherapy option in treating non-muscle invasive bladder cancer.
Read more →CGON▲ +8.6%on this news
CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates
CG Oncology reported its third quarter 2025 financial results, highlighting the initiation of a rolling Biologics License Application (BLA) for cretostimogene in high-risk non-muscle invasive bladder cancer (NMIBC). The company achieved a 41.8% complete response rate in a clinical trial and completed enrollment in a significant Phase 3 study ahead of schedule. Despite a net loss increase, CG Oncology maintains a strong cash position to support future operations.
Read more →CGON▲ +8.6%on this newsshared move
CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates • Initiated rolling Biologics License Application (BLA) submission to U.S. FDA for cretostimogene monotherapy in high-risk (HR
CG Oncology reported its financial results for Q3 2025, highlighting the initiation of a rolling Biologics License Application for cretostimogene in treating high-risk BCG-unresponsive non-muscle invasive bladder cancer. The company demonstrated a significant complete response rate of 41.8% in recent clinical trials and completed enrollment in a major Phase 3 study, PIVOT-006. Financially, CG Oncology maintains a robust cash position, projected to fund operations until mid-2028. However, the company also faces increased operational costs and an escalating net loss compared to the previous year.
Read more →CGONASCO-GU 2024POSTER AND MEETING PRESENTATION
CG Oncology is set to present at the ASCO-GU 2024 meeting, showcasing their latest research developments. This follows their recent positive results from the CORE-1008 Phase 2 trial, which evaluates a new therapy for high-risk bladder cancer patients. The company is actively participating in various conferences to share their findings.
Read more →CGONNCSAUA 2025- BOND-003 COHORT P PODIUM
The article announces the NCSAUA 2025 event featuring the BOND-003 Cohort P podium presentation. It is a press release that highlights the upcoming congress and provides links to additional resources such as a video library and career opportunities. No specific details about the presentation or its content are provided.
Read more →CGONWSAUA 2025 – PIVOT-006 UNMODERATED POSTER
The article announces the presentation of an unmoderated poster related to the PIVOT-006 study at the WSAUA 2025 conference. Details about the study or findings are not provided, focusing instead on the event itself. The announcement is part of ongoing communications from the organization.
Read more →CGONWSAUA 2025 – BOND-003 COHORT P MODERATED POSTER
The article announces the moderated poster presentation for the BOND-003 Cohort P at the WSAUA 2025 conference. Details about the content of the poster or its significance are not provided. The announcement is part of a broader communication strategy for the event.
Read more →CGONWSAUA 2025 – BOND-003 COHORT C MODERATED POSTER
The article announces a moderated poster presentation for the BOND-003 Cohort C at the WSAUA 2025 conference. The details are minimal, focusing primarily on the event's title and date. Further information about the content of the presentation or its significance is not provided.
Read more →CGONSIU 2025 – CORE-008 UNMODERATED POSTER
CG Oncology has announced positive initial results from the CORE-008 trial, which assesses an intravesical combination therapy for patients who are high-risk and have been exposed to or are unresponsive to BCG treatment. This development highlights the company's commitment to addressing unmet needs in bladder cancer treatment.
Read more →CGONSIU 2025- BOND-003 COHORT P MODERATED POSTER
The article announces the presentation of a moderated poster for the SIU 2025 BOND-003 Cohort P. It is part of a larger event and provides minimal details about the content of the poster or its implications. The announcement is primarily informational.
Read more →CGONSIU 2025- BOND-003 COHORT C MODERATED POSTER
The article discusses the SIU 2025 event featuring a moderated poster for the BOND-003 Cohort C. It highlights the event's focus on presenting research findings, although specific details about the content of the poster are not provided.
Read more →CGONNCSAUA 2025- BOND-003 COHORT C PODIUM
The article discusses the NCSAUA 2025 event featuring the BOND-003 Cohort C podium presentation. It highlights the significance of the event but lacks detailed information about the content or findings presented. The announcement is part of a broader communication strategy by the organization.
Read more →CGONSCSAUA 2025 – ENROLLMENT CHARACTERISTICS BOND-003 & CORE-001
The article discusses the enrollment characteristics for the SCSAUA 2025 event, specifically focusing on the BOND-003 and CORE-001 studies. It appears to be an informational release without significant updates or changes to report. The content is primarily administrative in nature, indicating ongoing preparations for the event.
Read more →CGONAttacking Bladder Cancer for a Better Tomorrow Disclaimer and Forward-Looking Statements We caution you that this presentation contains forward-looking statements about us and our industry. All statements other than stat
Crestostimogene grenadenorepvec is an investigational oncolytic immunotherapy currently undergoing clinical trials for Non-Muscle Invasive Bladder Cancer (NMIBC). The therapy shows promising outcomes, with noted high-grade recurrence-free survival rates and favorable safety profiles. However, the success of this candidate is crucial as it is the company's only product in development, with future milestones dependent on clinical trial progress and regulatory approvals.
Read more →CGON▲ +6.9%on this newsshared move
CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months
CG Oncology reported promising results from the BOND-003 Cohort C trial, showing a 41.8% complete response rate at 24 months for cretostimogene in patients with high-risk non-muscle invasive bladder cancer. The safety profile remains consistent, with no severe adverse events reported. The data highlights the potential of cretostimogene as a significant treatment option for patients unresponsive to BCG therapy.
Read more →CGONCG Oncology Completes Enrollment in PIVOT-006
CG Oncology has completed enrollment in its Phase 3 PIVOT-006 study, which evaluates the efficacy of cretostimogene grenadenorepvec in patients with intermediate-risk non-muscle invasive bladder cancer. The study aims to address the high recurrence rates and limited treatment options in this patient population. The rapid enrollment reflects a significant unmet need for new therapies in this area.
Read more →CGONCG Oncology’s Executive Leadership to Participate in Upcoming Investor Conferences
CG Oncology, Inc. announced that its CEO Arthur Kuan and COO Ambaw Bellete will participate in upcoming investor conferences. The company is focused on developing a potential bladder-sparing therapeutic for bladder cancer patients. Interested parties can access the live audio webcast from the company's website.
Read more →CGONCG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates
CG Oncology reported strong financial results for Q2 2025, highlighting best-in-disease durability data from the BOND-003 trial for cretostimogene. The company also announced a favorable verdict in its litigation with ANI Pharmaceuticals, allowing it to focus on advancing its bladder cancer treatment. CG Oncology is set to submit a Biologics License Application (BLA) for cretostimogene by the end of the year.
Read more →CGONDelaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals
CG Oncology has achieved a unanimous jury verdict in its favor, rejecting ANI Pharmaceuticals' claims for unjust enrichment and future royalties related to the drug cretostimogene grenadenorepvec. The court ruled that ANI is not entitled to any royalties on future sales, allowing CG Oncology to concentrate on its mission to develop therapies for bladder cancer. This decision is viewed as a significant win for patients awaiting innovative treatments.
Read more →CGONCG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
CG Oncology, a late-stage clinical biopharmaceutical company, will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025. CEO Arthur Kuan will lead a fireside chat, highlighting the company's focus on bladder cancer therapies. The event will be accessible via a live audio webcast.
Read more →CGONAUA 2025 BOND-003 COHORT C LATE-BREAKING PLENARY
The article announces the AUA 2025 BOND-003 Cohort C Late-Breaking Plenary session. It provides minimal details, primarily serving as a press release. The event is likely to showcase significant findings or updates related to the BOND-003 study. Further information about the session's content is not provided.
Read more →CGONAUA 2025 BOND-003 COHORT P LEARNING LAB
The article announces the AUA 2025 BOND-003 Cohort P Learning Lab, indicating a focus on educational presentations related to the event. It is part of the AUA congress activities, showcasing the ongoing efforts in the field. Further details about the presentations or outcomes are not provided.
Read more →CGONASCO 2025 CORE-008 MEETING SLIDERS & POSTER
The article announces the availability of meeting sliders and a poster for the ASCO 2025 CORE-008 event. It provides links to additional resources such as press releases and a video library. The announcement is brief and primarily serves as a notification for interested parties.
Read more →CGONAUA 2025 PIVOT-006 LEARNING LAB
CG Oncology is set to participate in the AUA 2025 PIVOT-006 Learning Lab. The company has recently reported positive results from its CORE-1008 Phase 2 trial, which evaluates a new intravesical combination therapy. Additionally, CG Oncology is involved in various upcoming investor conferences and has announced fellowship award recipients for NMIBC research.
Read more →CGONCG Oncology to Participate in the 2025 RBC Capital Markets Global Healthcare Conference
CG Oncology, a late-stage clinical biopharmaceutical company, will participate in a fireside chat at the 2025 RBC Capital Markets Global Healthcare Conference in New York. The event is scheduled for May 20, 2025, at 11:30 am ET, and will be accessible via a live audio webcast. This participation highlights the company's commitment to advancing treatments for bladder cancer.
Read more →CGONCG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates
CG Oncology reported its Q1 2025 financial results, highlighting significant advancements in its clinical trials for cretostimogene, an investigational therapy for non-muscle invasive bladder cancer (NMIBC). The company presented promising data at the AUA Annual Meeting, showing high response rates in its BOND-003 trial. Despite a net loss of $34.5 million, CG Oncology maintains a strong cash position to support ongoing operations and clinical development through 2028.
Read more →CGONCG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-mo
CG Oncology has reported its financial results for Q1 2025 and updates on its clinical programs. The latest findings from the BOND-003 trial highlight significant durability and tolerability of cretostimogene. Early results from another trial show a promising 90.5% high-grade recurrence-free survival rate. The company plans to submit a Biologics License Application (BLA) for cretostimogene later this year. Despite encouraging data, the company has reported a net loss and rising expenses, suggesting potential financial pressures ahead.
Read more →CGONSUO-CTC and CG Oncology Announce the 2025 Award Recipients for the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
CG Oncology and SUO-CTC have announced the recipients of the first annual NMIBC Research Fellowship, aimed at fostering clinical cancer research in non-muscle invasive bladder cancer. Drs. Ghodoussipour and Goodstein were awarded for their promising research plans. The fellowship highlights the commitment to improving bladder cancer treatment and patient outcomes.
Read more →CGON▲ +25%on this newsshared move
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting – Robust 2
CG Oncology has reported promising results for its investigational treatment, cretostimogene grenadenorepvec, at the AUA Annual Meeting. The Phase 3 BOND-003 Cohort C trial showed a robust complete response rate of 42.3% at 24 months, and 97.3% of patients maintained freedom from progression to muscle-invasive bladder cancer. Notably, no severe treatment-related adverse events occurred. Furthermore, early data from Cohort P suggests high-grade recurrence-free survival rates of 90.5% at 3 and 9 months, indicating significant potential for this therapy in the treatment of bladder cancer.
Read more →CGON▲ +25%on this newsshared move
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting
CG Oncology presented promising data for cretostimogene grenadenorepvec at the AUA Annual Meeting. The Phase 3 BOND-003 Cohort C study showed a 42.3% complete response rate at 24 months, with 97.3% of patients free from progression to muscle-invasive disease. Cohort P data indicated a 90.5% high-grade recurrence-free survival at 3 and 9 months. The treatment demonstrated a favorable safety profile with no significant adverse events reported.
Read more →CGON▲ +25%on this newsshared move
CG Oncology Announces…
CG Oncology announced promising results for cretostimogene grenadenorepvec at the 2025 AUA Annual Meeting. The Phase 3 BOND-003 Cohort C study demonstrated a 42.3% complete response rate at 24 months, with 97.3% of patients free from progression to muscle invasive disease. Additionally, Cohort P reported a high-grade recurrence-free survival of 90.5%. The treatment exhibited a favorable safety profile with no significant adverse events.
Read more →CGONHost Conference Call…
CG Oncology, Inc. will host a conference call and live webcast on April 28, 2025, to discuss results from the Phase 3 BOND-003 trial of cretostimogene for high-risk BCG-unresponsive non-muscle invasive bladder cancer. The results will be presented at the American Urological Association Annual Meeting on April 26, 2025. The webcast can be accessed through the company's Investor Relations website.
Read more →CGONEAU 2025 TRANSLATIONAL CORRELATES USING URINARY MRD
The article discusses the upcoming EAU 2025 conference, focusing on translational correlates using urinary minimal residual disease (MRD). It highlights the significance of this research in the field. Further details about presentations and related activities are mentioned, but specifics are limited.
Read more →CGONAUA 2025 TRANSLATIONAL CORRELATES USING URINARY MRD
The article discusses the AUA 2025 conference focusing on translational correlates using urinary minimal residual disease (MRD). It highlights the significance of this research area but lacks detailed information on findings or implications. The announcement is part of a broader agenda for the conference.
Read more →CGONEAU 2025 BOND-003 COHORT P TRIAL IN PROGRESS
The EAU 2025 BOND-003 Cohort P trial is currently underway, showcasing ongoing research efforts. This trial is part of a larger initiative presented at a significant congress event. The progress of this trial may contribute to advancements in the relevant field.
Read more →CGONEAU 2025 PIVOT-006 TRIAL IN PROGRESS
The EAU 2025 PIVOT-006 trial is currently underway, as announced in a recent press release. Details regarding the trial's objectives and methodology have not been disclosed. The announcement was made on April 3, 2025, indicating ongoing research efforts in this area.
Read more →CGON▼ -7.3%on this news· ran to -29% by day 3shared move
CG Oncology to Participate…
CG Oncology, Inc. will participate in the 120th American Urological Association Annual Meeting, where it will present significant findings from its BOND-003 study on cretostimogene for bladder cancer. The study has been chosen as a late breaker, highlighting its potential impact on urology practices. Additional updates on ongoing clinical trials will also be shared during the event.
Read more →CGONCG Oncology Reports 2024 Year End Financial Results and Provides Business Updates - Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Gu rin (BCG)-Unresponsive N
CG Oncology reported its 2024 year-end financial results, highlighting significant progress in its clinical trials for cretostimogene, an investigational therapy for non-muscle invasive bladder cancer (NMIBC). The monotherapy showed a 75.5% complete response rate in high-risk BCG-unresponsive patients, and the company initiated the CORE-008 clinical trial to explore new treatment avenues. Financially, CG Oncology completed an oversubscribed $238 million public equity offering, aiming to extend its operational runway and support ongoing clinical efforts. However, they reported a growing net loss and rising R&D and administrative costs.
Read more →CGONCANCER NETWORK
CG Oncology has announced positive preliminary results from its CORE-1008 Phase 2 trial, which evaluates an intravesical combination therapy for patients who are high-risk and either BCG-exposed or BCG-unresponsive. Additionally, the company will present at upcoming investor conferences and has recognized recipients for the NMIBC research fellowship.
Read more →CGONUROLOGY TIMES
CG Oncology's Cretostimogene grenadenorepvec continues to demonstrate positive efficacy and safety in its ongoing clinical evaluations. Recent updates include favorable results from the CORE-1008 Phase 2 trial, which focuses on high-risk patients. The company is also preparing for upcoming investor conferences and has announced fellowship award recipients for bladder cancer research.
Read more →CGON▲ +5.5%on this newsshared move
CURE
CG Oncology's Cretostimogene has demonstrated a durable response in patients with BCG-unresponsive bladder cancer. The company recently reported positive results from the CORE-1008 Phase 2 trial, which evaluates an intravesical combination therapy. Additionally, CG Oncology is actively participating in upcoming investor conferences and research fellowship awards.
Read more →CGON▲ +5.5%on this newsshared move
Cretostimogene Grenade…
CG Oncology announced promising results from the Phase 3 BOND-003 study of cretostimogene for high-risk non-muscle invasive bladder cancer. The study showed that 75.5% of patients achieved a complete response, with a median duration of response exceeding 28 months. The treatment demonstrated a strong safety profile, with no severe adverse events reported. Additionally, new data indicate that post-treatment precautions are not needed.
Read more →CGON▲ +5.5%on this newsshared move
Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy – Latest BOND-003 data show 75.5% of patients achieved a c
CG Oncology announced that in the Phase 3 BOND-003 study of cretostimogene grenadenorepvec, 75.5% of patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer achieved a complete response. The data presented at the EAU Congress indicate that the median duration of response exceeds 28 months, with no significant adverse treatment-related events reported. Additionally, translational data suggest that no close contact precautions are necessary post-treatment, highlighting the therapy's compelling safety and efficacy profile. Results are expected to further mature as the study continues.
Read more →CGONEAU 2025 LATE-BREAKING PRESENTATION
CG Oncology is set to present late-breaking findings at EAU 2025, showcasing their ongoing commitment to advancing bladder cancer treatment. The company recently reported positive results from the CORE-1008 trial, which evaluates intravesical combination therapy for high-risk patients. Additionally, CG Oncology will participate in various investor conferences in June.
Read more →CGONCG Oncology to Participate…
CG Oncology is set to participate in the 40th Annual European Association of Urology Congress in Madrid from March 21-24, 2025. The company will present a late-breaking abstract on BOND-003 Cohort C, along with three posters on cretostimogene grenadenorepvec, an investigational therapy for bladder cancer. This congress is a key event for healthcare professionals to discuss advancements in urological care.
Read more →CGONSUO 2024 TOPLINE RESULTS FROM BOND-003
The article announces the topline results from the BOND-003 study, which is part of the SUO 2024 conference. Further details regarding the findings and implications of the study are not provided in the text. The announcement is made by the admin on December 9, 2024.
Read more →CGON▼ -6.5%on this newsshared move
Groundbreaking Creto…
CG Oncology announced positive topline results from the Phase 3 BOND-003 trial, showing that 74.5% of patients with high-risk non-muscle invasive bladder cancer achieved a complete response to cretostimogene. The median duration of response exceeds 27 months, with favorable safety results. The data will be presented at the Society of Urologic Oncology meeting.
Read more →CGON▼ -6.5%on this newsshared move
SCRIP
CG Oncology has announced positive initial results from its CORE-1008 Phase 2 trial, which evaluates an intravesical combination therapy for patients with high-risk non-muscle invasive bladder cancer who are BCG-exposed and BCG-unresponsive. The company is also set to present at various upcoming investor conferences, highlighting its ongoing commitment to advancing cancer treatment.
Read more →CGON▼ -6.5%on this newsshared move
ENDPOINTS NEWS
CG Oncology's bladder cancer treatment has demonstrated potential durability in a Phase 3 trial. The company recently reported positive results from its CORE-1008 Phase 2 trial, which evaluated an intravesical combination therapy for high-risk patients. Additionally, CG Oncology is set to present at upcoming investor conferences, highlighting its ongoing commitment to advancing bladder cancer treatments.
Read more →CGON▼ -6.5%on this newsshared move
REUTERS
CG Oncology's experimental immunotherapy has shown promising results in treating bladder cancer, particularly in patients who are high-risk and have been exposed to BCG therapy. The company recently reported positive outcomes from its CORE-1008 trial, which evaluates an intravesical combination therapy. CG Oncology is also set to present at upcoming investor conferences.
Read more →CGON▼ -6.5%on this newsshared move
Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer 74.5% of patients achieved a complete res
CG Oncology announced positive topline data from the Phase 3 BOND-003 trial for cretostimogene grenadenorepvec in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer. The study showed that 74.5% of patients achieved a complete response, with the median duration of response surpassing 27 months. Notably, there were no severe adverse events reported, which highlights the treatment's safety profile. The findings will be presented at the Society of Urologic Oncology's annual meeting, and the company is optimistic about its potential to transform bladder cancer treatment if approved by the FDA.
Read more →CGON▼ -6.8%on this news· ran to -17% by day 3
CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates - Late-Breaking Abstract on Results of Phase 3 BOND-003 Trial of Cretostimogene Monotherapy in BCG-Unresponsive NMIBC Accepted at the
CG Oncology reported its financial results for Q3 2024, highlighting advancements in its treatment pipeline for Non-Muscle Invasive Bladder Cancer (NMIBC). Notably, the late-breaking abstract on the Phase 3 BOND-003 trial of cretostimogene was accepted at the Society of Urologic Oncology meeting. Despite a cash position sufficient to fund operations until 2027, the company reported a larger net loss this quarter compared to the previous year, influenced by increasing research and development expenses. The company remains optimistic about the potential of cretostimogene while acknowledging various operational challenges.
Read more →CGONNATURE MEDICINE
The article discusses the phase 2 CORE-001 trial, which investigates the efficacy of oncolytic adenoviral therapy combined with pembrolizumab for patients with BCG-unresponsive non-muscle-invasive bladder cancer. The trial aims to provide new treatment options for this challenging patient population. Recent results suggest positive outcomes, indicating a potential advancement in bladder cancer therapy.
Read more →CGON▲ +7%on this news
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates – Final positive safety and efficacy findings from CORE-001 study of Cretostimogene Grenadenorepvec in combination with Pembr
CG Oncology reported strong financial results and positive findings from the CORE-001 study of Cretostimogene Grenadenorepvec combined with Pembrolizumab for treating BCG-unresponsive NMIBC. The company achieved a 54% complete response rate, meeting the primary endpoint, and demonstrated a 75.2% response rate in a separate monotherapy study. Additionally, it initiated an Expanded Access Program to increase patient access to this investigational therapy. Despite these advancements, CG Oncology reported a net loss of $18.9 million, reflecting ongoing high costs associated with clinical trials.
Read more →CGONASCO-GU 2024 POSTER AND MEETING PRESENTATION
The article announces the upcoming ASCO-GU 2024 poster and meeting presentation. It provides minimal details, focusing on the event's scheduling. Further information regarding the content of the presentations or specific topics covered is not included.
Read more →CGONASCO 2024 POSTER AND MEETING PRESENTATION
The article announces the upcoming poster and meeting presentation at ASCO 2024. It is a press release that provides minimal details about the content of the presentation. The announcement is part of ongoing communications related to the event, but specific information is not disclosed.
Read more →CGON▲ +9.1%on this news
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting – 54% c
CG Oncology has announced promising final results from the Phase 2 CORE-001 study, demonstrating a 54% complete response rate at 24 months for their investigational therapy, cretostimogene, in combination with pembrolizumab for high-risk NMIBC patients. The data shows that 100% of patients were progression-free at 24 months, reinforcing the potential of cretostimogene as an effective treatment option. The findings will be presented at the ASCO 2024 Annual Meeting, where the company aims to highlight the therapy's safety and efficacy, along with plans for future trials.
Read more →CGONAUA 2024 PIVOTAL RESULTS FROM BOND-003
The article announces the pivotal results from the BOND-003 study to be presented at AUA 2024. Details regarding the study's findings or implications are not provided in the text. The announcement is part of a broader communication strategy for the event.
Read more →CGON▼ -7.4%on this news
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates Cretostimogene Monotherapy Demonstrated 75.2% Complete Response (CR) Rate at Any Time in Bacillus Calmette Guerin (BCG)-Unresponsive,
CG Oncology has reported its financial results for Q1 2024, highlighting the 75.2% complete response rate of cretostimogene in treating high-risk non-muscle invasive bladder cancer (HR-NMIBC). The company completed a successful $437 million IPO, enhancing its financial runway through 2027. CG Oncology is preparing to present final results from ongoing clinical trials by the end of the year, with notable milestones anticipated. However, the company cautioned that interim results may vary and that reliance on third parties involves inherent risks.
Read more →CGONAUA 2024 BOND-003 Cohort P PRESENTATION
The AUA 2024 event will feature a presentation on the BOND-003 Cohort P study. Details regarding the study's findings or implications were not provided in the announcement. The event aims to share insights and advancements in the field, but specific content remains unspecified.
Read more →CGONCG Oncology to Unveil…
CG Oncology announced that it will present final results from the CORE-001 Phase 2 trial of cretostimogene in combination with pembrolizumab at the ASCO 2024 Annual Meeting. This trial focuses on treating patients with BCG-unresponsive non-muscle invasive bladder cancer. The presentation is scheduled for June 2, 2024, highlighting the company's commitment to advancing bladder cancer therapies.
Read more →CGONONCLIVE
The FDA has granted Fast Track and Breakthrough Therapy designations to Cretostimogene Grenadenorepvec for the treatment of non-muscle invasive bladder cancer (NMIBC). These designations are expected to expedite the development and review process, enhancing treatment options for patients with high-risk conditions. This marks a significant advancement for CG Oncology in their therapeutic offerings.
Read more →CGONPHARMACEUTICAL TECHNOLOGY
CG Oncology has announced positive initial results from its CORE-1008 Phase 2 trial, which focuses on an intravesical combination therapy for patients with high-risk, BCG-exposed, and BCG-unresponsive non-muscle invasive bladder cancer. The company is also set to present at various upcoming investor conferences. This development highlights CG Oncology's commitment to advancing treatment options in oncology.
Read more →CGONCG Oncology Receives…
CG Oncology has received FDA Fast Track and Breakthrough Therapy Designations for cretostimogene grenadenorepvec, aimed at treating high-risk BCG-unresponsive Non-Muscle Invasive Bladder Cancer. The designations are intended to expedite the drug's development and review process. Recent Phase 3 trial results showed a promising 75.7% complete response rate, highlighting the drug's potential efficacy.
Read more →CGONSCIENCE
Cretostimogene grenadenorepvec is an innovative oncolytic immunotherapy targeting non-muscle invasive bladder cancer (NMIBC). It operates by replicating within tumor cells, leading to their destruction while also stimulating a systemic immune response. This dual mechanism may enhance treatment outcomes for patients, particularly in high-risk populations.
Read more →CGONUROTODAY
CG Oncology has announced positive initial results from its CORE-1008 Phase 2 trial, which assesses an intravesical combination therapy for patients with high-risk BCG-exposed and BCG-unresponsive non-muscle invasive bladder cancer. This development is a significant step forward in addressing treatment challenges in this patient population. The company is also set to present at upcoming investor conferences.
Read more →CGONCretostimogene Grena…
CG Oncology announced positive interim results from the Phase 3 BOND-003 trial for cretostimogene grenadenorepvec, showing a 75.7% complete response rate in patients with high-risk BCG-unresponsive non-muscle-invasive bladder cancer. The data will be presented at the Society of Urological Oncology Annual Meeting. The trial enrolled 116 patients, and the treatment was well tolerated with minimal adverse effects.
Read more →CGONJOURNAL OF UROLOGY 2012 PUBLICATION
The article mentions a publication in the Journal of Urology from 2012, but lacks specific details about the content or significance of the publication. It appears to be an announcement or reference without further elaboration on findings or implications. Additional context or information is not provided.
Read more →CGONFRONTIERS IN ONCOLOGY 2014 PUBLICATION
The article announces a publication related to Frontiers in Oncology from 2014. It appears to be a press release without detailed content provided. The publication may contain relevant findings or discussions pertinent to oncology, but specifics are not included in the text.
Read more →CGONFORBES
CG Oncology has announced positive initial results from its CORE-1008 Phase 2 trial, which evaluates an intravesical combination therapy for patients who are high-risk and BCG-exposed or unresponsive. The company is set to present these findings at upcoming investor conferences, showcasing its advancements in bladder cancer treatment.
Read more →CGONFIERCE BIOTECH
CG Oncology has successfully secured $105 million in funding to support its Phase 3 trial for bladder cancer. This significant investment aims to advance research and treatment options for patients suffering from this condition. The funding is expected to enhance the company's capabilities in addressing unmet medical needs in oncology.
Read more →CGONTARGETED ONCOLOGY
CG Oncology has announced positive initial results from its CORE-1008 Phase 2 trial, which evaluates an intravesical combination therapy for patients who are high-risk and either BCG-exposed or BCG-unresponsive. The company is also set to present at various upcoming investor conferences, showcasing its commitment to advancing treatment options in oncology.
Read more →CGONCG Oncology Completes…
CG Oncology has successfully completed patient enrollment for the BOND-003 Phase 3 study, which evaluates cretostimogene grenadenorepvec in patients with BCG-unresponsive high-risk non-muscle invasive bladder cancer. A total of 110 patients have been enrolled across North America and the Asia-Pacific regions. The study's primary endpoint is complete response, with several secondary endpoints aimed at assessing the treatment's effectiveness and safety.
Read more →Competitive Position
How CGON ranks across every disease it competes inCompetitive Position is a premium feature
See how CGON ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial